{"title":"Transient hypogammaglobulinemia of infancy: revisiting an old entity.","authors":"Zehra Genç Ozbay, Saliha Esenboga","doi":"10.1080/1744666X.2026.2742255","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Transient hypogammaglobulinemia of infancy (THI) is one of the most common primary antibody deficiencies presenting in early childhood and is characterized by delayed maturation of humoral immunity with spontaneous normalization of immunoglobulin G (IgG) levels in most patients. Although THI has traditionally been considered a benign, self-limited disorder, increasing evidence suggests that it represents a heterogeneous immunologic condition with variable clinical manifestations, immune abnormalities, and long-term outcomes.</p><p><strong>Areas covered: </strong>This narrative review summarizes evidence identified through PubMed/MEDLINE searches from database inception to July 2026 using terms related to THI, supplemented by manual screening of reference lists. Clinical manifestations range from asymptomatic disease to recurrent respiratory tract infections, wheezing, otitis media, sinusitis, atopic disease, and, less commonly, autoimmune or inflammatory complications. A major clinical challenge is differentiating THI from persistent primary antibody deficiencies, particularly common variable immunodeficiency, during early childhood. Because definitive diagnosis can only be established retrospectively after normalization of immunoglobulin levels, careful longitudinal clinical and immunologic follow-up remains essential.</p><p><strong>Expert opinion: </strong>Advances in immunophenotyping and molecular profiling are improving our understanding of THI pathogenesis and may facilitate the identification of biomarkers that distinguish transient immune delay from evolving primary immunodeficiency, supporting earlier diagnosis and more individualized follow-up.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":4.0000,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2026.2742255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Transient hypogammaglobulinemia of infancy (THI) is one of the most common primary antibody deficiencies presenting in early childhood and is characterized by delayed maturation of humoral immunity with spontaneous normalization of immunoglobulin G (IgG) levels in most patients. Although THI has traditionally been considered a benign, self-limited disorder, increasing evidence suggests that it represents a heterogeneous immunologic condition with variable clinical manifestations, immune abnormalities, and long-term outcomes.
Areas covered: This narrative review summarizes evidence identified through PubMed/MEDLINE searches from database inception to July 2026 using terms related to THI, supplemented by manual screening of reference lists. Clinical manifestations range from asymptomatic disease to recurrent respiratory tract infections, wheezing, otitis media, sinusitis, atopic disease, and, less commonly, autoimmune or inflammatory complications. A major clinical challenge is differentiating THI from persistent primary antibody deficiencies, particularly common variable immunodeficiency, during early childhood. Because definitive diagnosis can only be established retrospectively after normalization of immunoglobulin levels, careful longitudinal clinical and immunologic follow-up remains essential.
Expert opinion: Advances in immunophenotyping and molecular profiling are improving our understanding of THI pathogenesis and may facilitate the identification of biomarkers that distinguish transient immune delay from evolving primary immunodeficiency, supporting earlier diagnosis and more individualized follow-up.
期刊介绍:
Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.
Articles focus on the following key areas:
• Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines
• Performance and benefits of newly approved therapeutic agents
• New diagnostic approaches
• Screening and patient stratification
• Pharmacoeconomic studies
• New therapeutic indications for existing therapies
• Adverse effects, occurrence and reduction
• Prospects for medicines in late-stage trials approaching regulatory approval
• Novel treatment strategies
• Epidemiological studies
• Commentary and comparison of treatment guidelines
Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.